The moves come as Bayer seeks approval from Berkeley leaders for a new 30-year master plan that would allow the Germany-based company to build 1 million square feet of production, research and office space and add some 1,000 employees over that period.
At the forefront of Bayer's big plans are cell therapies, which employ genetically engineered cells to fix blood cancers and potentially more diseases, and one-shot-and-done gene therapies that insert a correct copy of a gene to replace a defective, disease-causing gene.
Sophie and her husband are set to spend more than £100,000 in travel and medical bills as they fly between England and the US in their bid to have another child.
The couple are undergoing IVF treatment in New York...
In a small, preliminary study, an experimental gene-editing treatment dramatically lowered cholesterol levels, perhaps permanently, after just one infusion, scientists reported on Monday.
If confirmed in larger studies, researchers hope the findings may lead to a one-and-done way to prevent...
By Nanette Elster, Kayhan Parsi, and Art Caplan, The American Journal of Bioethics | 05.06.2026
Aggregated News
“Better babies.” “Fitter families.” “Survival of the fittest.” “Three generations of imbeciles are enough.” These phrases are not merely historical reminders of the United States’ regrettable eugenic past but are appearing in an increasingly eugenic present. Eugenics may have seemed...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.
